Van ECK Associates Corp Acquires Shares of 140,154 TG Therapeutics, Inc. (NASDAQ:TGTX)

Van ECK Associates Corp purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 140,154 shares of the biopharmaceutical company's stock, valued at approximately $4,219,000. Van ECK Associates Corp owned approximately 0.09% of TG Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TGTX. State Street Corp boosted its stake in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after purchasing an additional 2,398,015 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after acquiring an additional 725,371 shares during the period. Public Sector Pension Investment Board acquired a new position in shares of TG Therapeutics in the third quarter worth approximately $6,619,000. JPMorgan Chase & Co. lifted its stake in shares of TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after acquiring an additional 270,286 shares during the period. Finally, PFM Health Sciences LP acquired a new position in shares of TG Therapeutics in the third quarter worth approximately $5,459,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Sean A. Power sold 11,337 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now owns 670,632 shares in the company, valued at $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 10.50% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. StockNews.com lowered TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, The Goldman Sachs Group boosted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Trading Down 0.2 %

TGTX traded down $0.06 during trading on Friday, hitting $30.88. The company's stock had a trading volume of 1,659,954 shares, compared to its average volume of 1,631,928. TG Therapeutics, Inc. has a twelve month low of $12.90 and a twelve month high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock's fifty day moving average price is $31.07 and its 200-day moving average price is $27.78. The firm has a market capitalization of $4.81 billion, a P/E ratio of -308.77 and a beta of 2.26.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.